Table 3 Summary of the switch from vaccination schemes based on the pentavalent vaccine with whole-cell pertussis component (wP) plus various combinations/presentations of IPV or OPV vaccines assessed in scenarios 1 to 4 to the hexavalent vaccine with acellular pertussis component (aP) and IPV